$PRTA
PROTHENA CORP PUBLIC LTD CO

2020 Q2 Form 10-Q Financial Statement

#000155905320000026 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $195.0K $167.0K
YoY Change 16.77% -40.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.660M $9.080M
YoY Change 6.39% -17.38%
% of Gross Profit
Research & Development $17.27M $9.583M
YoY Change 80.23% -69.53%
% of Gross Profit
Depreciation & Amortization $400.0K $400.0K
YoY Change 0.0% -50.0%
% of Gross Profit
Operating Expenses $26.93M $18.66M
YoY Change 44.27% -70.54%
Operating Profit -$26.73M -$18.50M
YoY Change 44.52% -70.67%
Interest Expense $180.0K $2.300M
YoY Change -92.17% 177.11%
% of Operating Profit
Other Income/Expense, Net $195.0K $2.531M
YoY Change -92.3% 103.95%
Pretax Income -$26.54M -$15.97M
YoY Change 66.21% -74.18%
Income Tax -$255.0K -$156.0K
% Of Pretax Income
Net Earnings -$26.28M -$15.81M
YoY Change 66.24% -73.6%
Net Earnings / Revenue -13477.95% -9467.07%
Basic Earnings Per Share -$0.66 -$0.40
Diluted Earnings Per Share -$0.66 -$0.40
COMMON SHARES
Basic Shares Outstanding 39.91M shares 39.86M shares
Diluted Shares Outstanding 39.91M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $333.9M $398.1M
YoY Change -16.13% -18.12%
Cash & Equivalents $333.9M $398.1M
Short-Term Investments
Other Short-Term Assets $7.100M $3.462M
YoY Change 105.08% -55.62%
Inventory
Prepaid Expenses
Receivables $56.00K
Other Receivables $0.00
Total Short-Term Assets $341.1M $418.7M
YoY Change -18.53% -15.25%
LONG-TERM ASSETS
Property, Plant & Equipment $3.215M $4.318M
YoY Change -25.54% -91.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $304.0K $923.0K
YoY Change -67.06% 83.86%
Total Long-Term Assets $37.81M $43.36M
YoY Change -12.81% -37.39%
TOTAL ASSETS
Total Short-Term Assets $341.1M $418.7M
Total Long-Term Assets $37.81M $43.36M
Total Assets $378.9M $462.1M
YoY Change -17.99% -17.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.124M $1.525M
YoY Change 39.28% -84.83%
Accrued Expenses $14.80M $10.00M
YoY Change 48.0% -29.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $18.54M $28.02M
YoY Change -33.81% -39.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $553.0K $553.0K
YoY Change 0.0% -99.5%
Total Long-Term Liabilities $125.9M $131.2M
YoY Change -4.04% -18.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.54M $28.02M
Total Long-Term Liabilities $125.9M $131.2M
Total Liabilities $144.5M $159.3M
YoY Change -9.28% -23.17%
SHAREHOLDERS EQUITY
Retained Earnings -$721.7M -$630.9M
YoY Change 14.4% 14.5%
Common Stock $399.0K $399.0K
YoY Change 0.0% 0.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $234.4M $302.8M
YoY Change
Total Liabilities & Shareholders Equity $378.9M $462.1M
YoY Change -17.99% -17.97%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$26.28M -$15.81M
YoY Change 66.24% -73.6%
Depreciation, Depletion And Amortization $400.0K $400.0K
YoY Change 0.0% -50.0%
Cash From Operating Activities -$18.69M -$12.10M
YoY Change 54.46% -120.82%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$70.00K
YoY Change -28.57% -30.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$50.00K -$70.00K
YoY Change -28.57% -30.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 210.0K
YoY Change -100.0% -124.42%
NET CHANGE
Cash From Operating Activities -18.69M -12.10M
Cash From Investing Activities -50.00K -70.00K
Cash From Financing Activities 0.000 210.0K
Net Change In Cash -18.74M -11.96M
YoY Change 56.69% -120.92%
FREE CASH FLOW
Cash From Operating Activities -$18.69M -$12.10M
Capital Expenditures -$50.00K -$70.00K
Free Cash Flow -$18.64M -$12.03M
YoY Change 54.95% -120.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001559053
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 prta Buildtosuit Lease Termof Contract
BuildtosuitLeaseTermofContract
P7Y9M30D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35676
dei Entity Registrant Name
EntityRegistrantName
PROTHENA CORPORATION PUBLIC LIMITED COMPANY
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1111119
dei Entity Address Address Line1
EntityAddressAddressLine1
77 Sir John Rogerson’s Quay, Block C
dei Entity Address Address Line2
EntityAddressAddressLine2
Grand Canal Docklands
dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 2,
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D02 T804,
dei Entity Address Country
EntityAddressCountry
IE
dei Country Region
CountryRegion
353
dei City Area Code
CityAreaCode
1
dei Local Phone Number
LocalPhoneNumber
236-2500
dei Security12b Title
Security12bTitle
Ordinary Shares, par value $0.01 per share
dei Trading Symbol
TradingSymbol
PRTA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39911413 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
333942000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
375723000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
56000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
68000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7125000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2584000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
341123000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
378375000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3215000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3874000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20570000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23274000 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
11017000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9956000 USD
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2704000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2704000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
304000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1085000 USD
CY2020Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
37810000 USD
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
40893000 USD
CY2020Q2 us-gaap Assets
Assets
378933000 USD
CY2019Q4 us-gaap Assets
Assets
419268000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2124000 USD
CY2019Q4 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2020Q2 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1242000 USD
CY2020Q2 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6152000 USD
CY2019Q4 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
5826000 USD
CY2020Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
221000 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
5000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5304000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5101000 USD
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4743000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5540000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18544000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17714000 USD
CY2020Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
110242000 USD
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
110242000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15150000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17838000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
553000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
553000 USD
CY2020Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
125945000 USD
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
128633000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
144489000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
146347000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2020Q2 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2020Q2 prta Deferred Shares Value
DeferredSharesValue
0 USD
CY2019Q4 prta Deferred Shares Value
DeferredSharesValue
0 USD
CY2020Q2 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2020Q2 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2019Q4 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2019Q4 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2019Q4 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2020Q2 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2020Q2 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2020Q2 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
CY2019Q4 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
CY2019Q4 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
399000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
399000 USD
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39911413 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39911413 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39911413 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39911413 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39898561 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39898561 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39898561 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39898561 shares
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
955781000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
944407000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-721736000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-671885000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
234444000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
272921000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
378933000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
419268000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
195000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
167000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
336000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
353000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17271000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9583000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32519000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22879000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9656000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9081000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19397000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18986000 USD
CY2020Q2 us-gaap Restructuring Costs
RestructuringCosts
0 USD
CY2019Q2 us-gaap Restructuring Costs
RestructuringCosts
0 USD
us-gaap Restructuring Costs
RestructuringCosts
0 USD
us-gaap Restructuring Costs
RestructuringCosts
-61000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
26927000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
18664000 USD
us-gaap Operating Expenses
OperatingExpenses
51916000 USD
us-gaap Operating Expenses
OperatingExpenses
41804000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26732000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18497000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-51580000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-41451000 USD
CY2020Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
179000 USD
CY2019Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2296000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1316000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4600000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
235000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
218000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
195000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2531000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1308000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4818000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-26537000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15966000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-50272000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-36633000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-255000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-156000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-421000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-15810000 USD
us-gaap Net Income Loss
NetIncomeLoss
-49851000 USD
us-gaap Net Income Loss
NetIncomeLoss
-36675000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39911000 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39872000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39910000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39868000 shares
us-gaap Net Income Loss
NetIncomeLoss
-49851000 USD
us-gaap Net Income Loss
NetIncomeLoss
-36675000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
765000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
772000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11223000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
12482000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1061000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-784000 USD
prta Amortizationofrightofuseasset
Amortizationofrightofuseasset
2704000 USD
prta Amortizationofrightofuseasset
Amortizationofrightofuseasset
2603000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-12000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3760000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
15593000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
589000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10414000 USD
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
0 USD
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-461000 USD
prta Increase Decreasein Operating Lease Liability
IncreaseDecreaseinOperatingLeaseLiability
2485000 USD
prta Increase Decreasein Operating Lease Liability
IncreaseDecreaseinOperatingLeaseLiability
2298000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41864000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29538000 USD
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
68000 USD
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
200000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-68000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-192000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
151000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
215000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
151000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
215000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41781000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29515000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
378427000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
431715000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336646000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
402200000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
417000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
755000 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
43000 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
12000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
28530000 USD
prta Reductionof Buildtosuit Lease Obligation
ReductionofBuildtosuitLeaseObligation
0 USD
prta Reductionof Buildtosuit Lease Obligation
ReductionofBuildtosuitLeaseObligation
51546000 USD
prta Reductionof Amounts Capitalized Under Buildtosuit Lease Transaction
ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction
0 USD
prta Reductionof Amounts Capitalized Under Buildtosuit Lease Transaction
ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction
46760000 USD
prta Reductionof Capitalized Interest During Construction Periodfor Buildtosuit Lease Transaction
ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction
0 USD
prta Reductionof Capitalized Interest During Construction Periodfor Buildtosuit Lease Transaction
ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction
1099000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
333942000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
398144000 USD
CY2020Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 USD
CY2019Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
1352000 USD
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2704000 USD
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2704000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336646000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
402200000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
255039000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5687000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-26282000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
234444000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
312130000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6277000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
210000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-15810000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
302807000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
272921000 USD
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11223000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
151000 USD
us-gaap Net Income Loss
NetIncomeLoss
-49851000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
234444000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
322998000 USD
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
12482000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
215000 USD
us-gaap Net Income Loss
NetIncomeLoss
-36675000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
302807000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-721700000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
333900000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment and Concentration of Risks</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The receivables recorded in the Condensed Consolidated Balance Sheet include amounts due from a Roche entity located in Switzerland. Revenue recorded in the Condensed Consolidated Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As of June 30, 2020, $3.2 million of the Company’s property and equipment, net were held in the U.S. and none were in Ireland. As of December 31, 2019, $3.9 million of the Company's property and equipment, net were held in the U.S. and none were in Ireland. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</span></div>
CY2020Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
9334000 USD
CY2019Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
9312000 USD
CY2020Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1261000 USD
CY2019Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1261000 USD
CY2020Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
1392000 USD
CY2019Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
1308000 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11987000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11881000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8772000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8007000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3215000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3874000 USD
CY2020Q2 us-gaap Depreciation
Depreciation
400000 USD
us-gaap Depreciation
Depreciation
800000 USD
CY2019Q2 us-gaap Depreciation
Depreciation
400000 USD
us-gaap Depreciation
Depreciation
800000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3355000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4818000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
715000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
400000 USD
CY2020Q2 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
673000 USD
CY2019Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
322000 USD
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4743000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5540000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-15810000 USD
us-gaap Net Income Loss
NetIncomeLoss
-49851000 USD
us-gaap Net Income Loss
NetIncomeLoss
-36675000 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39911000 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39872000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39910000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39868000 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1600000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
3200000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1600000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
3200000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1500000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
3000000.0 USD
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1400000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
2900000 USD
CY2016Q1 prta Operating Lease Area
OperatingLeaseArea
128751 sqft
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2016Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-12-31
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
39200000 USD
CY2016 prta Operating Leases Improvement Allowance
OperatingLeasesImprovementAllowance
14200000 USD
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2700000 USD
CY2018Q3 prta Operating Leases Sublease Rentals Areaof Sublease Rental
OperatingLeasesSubleaseRentalsAreaofSubleaseRental
46641 sqft
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
700000 USD
us-gaap Sublease Income
SubleaseIncome
1500000 USD
CY2019Q2 us-gaap Sublease Income
SubleaseIncome
700000 USD
us-gaap Sublease Income
SubleaseIncome
1500000 USD
CY2018Q3 prta Subleaserentals Annual Base Rent Initial Amount
SubleaserentalsAnnualBaseRentInitialAmount
2700000 USD
CY2018Q3 prta Operating Leases Sublease Rentals Percent Annual Rent Increase
OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease
0.035
CY2018Q3 prta Operating Leases Sublease Rentals Termof Contract
OperatingLeasesSubleaseRentalsTermofContract
P5Y2M12D
CY2018Q3 prta Operating Leases Sublease Rentals Percentof Rental Gain Attributableto Sublandlord
OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord
0.50
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3040000 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
1438000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6165000 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
2944000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6350000 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
3047000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6535000 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
3019000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
22090000 USD
CY2020Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
10448000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1625000 USD
CY2020Q2 prta Lessee Operating Lease Liability Nominal Payments
LesseeOperatingLeaseLiabilityNominalPayments
11000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
20454000 USD
CY2020Q2 us-gaap Purchase Obligation
PurchaseObligation
4000000.0 USD
CY2020Q2 us-gaap Purchase Obligation
PurchaseObligation
3959000 USD
CY2020Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
3959000 USD
CY2020Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 USD
CY2020Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 USD
CY2020Q2 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 USD
CY2020Q2 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
0 USD
CY2020Q2 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
0 USD
CY2020Q2 prta Purchaseand Contractual Obligation Total
PurchaseandContractualObligationTotal
5034000 USD
CY2020Q2 prta Purchaseand Contractual Obligation Remainderof Fiscal Year
PurchaseandContractualObligationRemainderofFiscalYear
4244000 USD
CY2020Q2 prta Purchaseand Contractual Obligation Duein Second Year
PurchaseandContractualObligationDueinSecondYear
95000 USD
CY2020Q2 prta Purchaseand Contractual Obligation Duein Third Year
PurchaseandContractualObligationDueinThirdYear
80000 USD
CY2020Q2 prta Purchaseand Contractual Obligation Duein Fourth Year
PurchaseandContractualObligationDueinFourthYear
80000 USD
CY2020Q2 prta Purchaseand Contractual Obligation Duein Fifth Year
PurchaseandContractualObligationDueinFifthYear
70000 USD
CY2020Q2 prta Purchaseand Contractual Obligation Due After Fifth Year
PurchaseandContractualObligationDueAfterFifthYear
465000 USD
CY2020Q2 prta Collaboration Revenue
CollaborationRevenue
100000 USD
prta Collaboration Revenue
CollaborationRevenue
300000 USD
CY2019Q2 prta Collaboration Revenue
CollaborationRevenue
200000 USD
prta Collaboration Revenue
CollaborationRevenue
400000 USD
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
26.35
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39911413 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39911413 shares
prta Numberof Votes
NumberofVotes
1 vote
CY2020Q2 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2020Q2 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2020Q2 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
263500 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
145000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1718950 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
997975 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8672205 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.09
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
41800000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M17D
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
5687000 USD
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
6277000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11223000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
12482000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.796
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.815
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.812
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.815
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.022
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.025
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.52
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.06
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7008403 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.34
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M26D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11901000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1718950 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.87
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12852 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20960 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
21336 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
33.61
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8672205 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.09
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M13D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2426000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8194918 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
21.50
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M7D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2407000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
4500202 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y14D
CY2020Q2 prta Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions
2254000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-255000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-421000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-156000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42000 USD
CY2020Q2 prta Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
0 USD
prta Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
100000 USD
CY2019Q2 prta Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
300000 USD
prta Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
1000000.0 USD

Files In Submission

Name View Source Status
0001559053-20-000026-index-headers.html Edgar Link pending
0001559053-20-000026-index.html Edgar Link pending
0001559053-20-000026.txt Edgar Link pending
0001559053-20-000026-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
prta-20200630.htm Edgar Link pending
prta-20200630.xsd Edgar Link pending
prta-20200630_cal.xml Edgar Link unprocessable
prta-20200630_def.xml Edgar Link unprocessable
prta-20200630_htm.xml Edgar Link completed
prta-20200630_lab.xml Edgar Link unprocessable
prta-20200630_pre.xml Edgar Link unprocessable
prta2020q210-qxex102fi.htm Edgar Link pending
prta2020q210-qxex10320.htm Edgar Link pending
prta2020q210-qxex311.htm Edgar Link pending
prta2020q210-qxex312.htm Edgar Link pending
prta2020q210-qxex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending